Cargando…
From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine
Cancer drug discovery is an inefficient process, with more than 90% of newly-discovered therapies failing to gain regulatory approval. Patient-derived models of cancer offer a promising new approach to identify new treatments; however, for rare cancers, such as sarcomas, access to patient samples is...
Autores principales: | Rao, Sneha R., Somarelli, Jason A., Altunel, Erdem, Selmic, Laura E., Byrum, Mark, Sheth, Maya U., Cheng, Serene, Ware, Kathryn E., Kim, So Young, Prinz, Joseph A., Devos, Nicolas, Corcoran, David L., Moseley, Arthur, Soderblom, Erik, Hsu, S. David, Eward, William C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026496/ https://www.ncbi.nlm.nih.gov/pubmed/32117764 http://dx.doi.org/10.3389/fonc.2020.00117 |
Ejemplares similares
-
A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma
por: Somarelli, Jason A., et al.
Publicado: (2020) -
Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer
por: Altunel, Erdem, et al.
Publicado: (2020) -
Exome sequencing of hepatocellular carcinoma in lemurs identifies potential cancer drivers: A pilot study
por: Gunady, Ella F, et al.
Publicado: (2022) -
Editorial: Pharmacogenomics: From Bench to Bedside and Back Again
por: Shaman, Jeffrey A., et al.
Publicado: (2022) -
An integrated comparative physiology and molecular approach pinpoints mediators of breath-hold capacity in dolphins
por: Blawas, Ashley M, et al.
Publicado: (2021)